Business

Dr Reddy’s launches anaesthetic in US

Dr Reddy’s Laboratories announced the launch of Propofol Injectable Emulsion, used for induction of general anaesthesia and sedation in intensive care units, in the US market.

migrator

Mumbai

Propofol Injectable Emulsion is a therapeutic equivalent generic version of Diprivan (Propofol) Injectable Emulsion,” the company said in a BSE filing. Dr Reddy’s said it uses distribution controls to market Propofol Injectable Emulsion, USP, to prevent any misuse. “Dr Reddy’s will not accept orders from correctional facilities and prison systems whose intended use of the product is to aid in lethal injection.

We require the same commitment from our wholesalers and distributors,” the company said. Quoting IMS Health MAT data for twelve months ending in November 2018, Dr Reddy’s Laboratories said Diprivan brand and generic had US sales of approximately $310 million. Shares of Dr Reddy’s were trading 0.49 per cent higher at Rs 2,658.45 apiece on the BSE.

Visit news.dtnext.in to explore our interactive epaper!

Download the DT Next app for more exciting features!

Click here for iOS

Click here for Android

Also Read

VB-G RAM-G replaces MGNREGA with President's assent, gazette notification

GCC seeks police inquiry into wage theft scam by Parks department contractors

TN Minister TRB Rajaa inspects Madurai Tidel Park works

Erode meeting testimony to Vijay's actor-to-politician transformation, claims TVK leader Arunraj

Tamil Nadu's first play park for pet dogs opened in Ooty